Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis

Matteo Morotti, Venturini PL, Pier Luigi Venturini, Ennio Biscaldi, Biscaldi E, Annalisa Racca, Racca A, Calanni L, Luana Calanni, Valerio Gaetano Vellone, Stabilini C, Cesare Stabilini, Simone Ferrero
European journal of obstetrics, gynecology, and reproductive biology · 2017 · vol. 213 , pp. 4–10 · doi:10.1016/j.ejogrb.2017.03.033 · PMID:28384540 · W2602194673
Other OA: closed CC0 ⤵ 29 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study evaluated the long-term efficacy and acceptability of norethindrone acetate in treating rectovaginal endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To study the efficacy of long-term treatment with norethindrone acetate (NETA) in patients with rectovaginal endometriosis. STUDY DESIGN: This retrospective cohort study included 103 women with pain symptoms caused by rectovaginal endometriosis. Patients received NETA alone (2.5mg/day up to 5mg/day) for 5 years. Primary outcome was the degree of satisfaction with treatment after 5 years of progestin therapy. Secondary outcomes were the assessment of any variation in pain symptoms and the volumetric assessment of the disease by magnetic resonance imaging (MRI). RESULTS: Sixty-one women completed the 5-year follow-up (61/103, 59.2%) with 16 women withdrawing because of adverse effects (38.1%). Overall, 68.8% (42/61) of the women who completed the study were satisfied or very satisfied of this long term NETA treatment. This represents a 40.8% (42/103) of the patients enrolled. Intensity of chronic pelvic pain and deep dyspareunia significantly decreased during treatment (p<0.001 versus baseline at 1 and 5year). Dyschezia improved after 1-year respect to baseline (p=0.008) but remained stable between first and second year (p=0.409). At the end of 5 years treatment, a radiological partial response was observed in 33 patients (55.9%, n 33/59); a stable disease in 19 patients (32.2%, n 19/59). Seven women (7/59, 11.9%) displayed a volumetric increase of rectovaginal endometriosis under NETA treatment. CONCLUSION: Five-year therapy with NETA is safe and well tolerated by women with rectovaginal endometriosis. Due to its low cost and good pharmacological profile, it represents a good candidate for long-term treatment in this setting.

My notes (saved in your browser only)

Condition tags

dyspareuniaendometriosischronic_pelvic_painbowel_endometriosis

MeSH descriptors

Endometriosis Norethindrone Rectal Diseases Vaginal Diseases Adult Adult Cohort Studies Cohort Studies Dyspareunia Dyspareunia Dyspareunia Endometriosis Endometriosis Endometriosis Endometriosis Female Female Humans Humans Norethindrone

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (37)

Cited by (29)

Source provenance

europepmc
last seen: 2026-10-16T06:09:50.462052+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:19:42.633400+00:00
License: CC0 · commercial use OK